DOCSLIB.ORG

Genetic Basis of Human Congenital Heart Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetic Basis of Human Congenital Heart Disease This is a free sample of content from Heart Development and Disease. Click here for more information on how to buy the book. Genetic Basis of Human Congenital Heart Disease Shannon N. Nees1 and Wendy K. Chung1,2 1Department of Pediatrics,2Department of Medicine, Columbia University Irving Medical Center, New York, New York 10032, USA Correspondence: [email protected] Congenital heart disease (CHD) is the most common major congenital anomaly with an incidence of ∼1% of live births and is a significant cause of birth defect–related mortality. The genetic mechanisms underlying the development of CHD are complex and remain incompletely understood. Known genetic causes include all classes of genetic variation in- cluding chromosomal aneuploidies, copy number variants, and rare and common single- nucleotide variants, which can be either de novo or inherited. Among patients with CHD, ∼8%–12% have a chromosomal abnormality or aneuploidy, between 3% and 25% have a copy number variation, and 3%–5% have a single-gene defect in an established CHD gene with higher likelihood of identifying a genetic cause in patients with nonisolated CHD. These genetic variants disrupt or alter genes that play an important role in normal cardiac develop- ment and in some cases have pleiotropic effects on other organs. This work reviews some of the most common genetic causes of CHD as well as what is currently known about the underlying mechanisms. ongenital heart disease (CHD) is the most are underdeveloped left-sided cardiac structures Ccommon major congenital anomaly with an and only a single functioning ventricle. The high incidence of ∼1% of live births (Hoffman and concordance in monozygotic twins, the in- Kaplan 2002; Calzolari et al. 2003). CHD is a creased risk of recurrence in first-degree relatives significant cause of birth defect–related mortal- compared with the general population, and ge- ity (Hanna et al. 1994; Lee et al. 2001; Hoffman netic syndromes associated with specific types of and Kaplan 2002; Calzolari et al. 2003; Centers CHD all suggest a genetic component to CHD in for Disease Control and Prevention (CDC) at least some cases (Nora et al. 1988). The genes 2007; van der Linde et al. 2011; Gilboa et al. and genetic mechanisms underlying CHD are 2016). CHD encompasses any malformation of complex and remain incompletely understood, the cardiovascular system present at birth, and but our understanding has improved signifi- there are many subtypes ranging from relatively cantly over the past decade. All classes of genetic simple lesions such as atrial and ventricular sep- variation including chromosomal aneuploidies, tal defects to complex lesions such as hypoplas- copy number variants (CNVs), and rare and tic left heart syndrome (HLHS) in which there common de novo and inherited single-nucleo- Copyright © 2020 Cold Spring Harbor Laboratory Press; all rights reserved Cite this article as Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a036749 283 © 2020 by Cold Spring Harbor Laboratory Press. All rights reserved. This is a free sample of content from Heart Development and Disease. Click here for more information on how to buy the book. S.N. Nees and W.K. Chung tide variants (SNVs) contribute to CHD (Thien- The overall incidence of CHD is similar be- pont et al. 2007; Erdogan et al. 2008; Southard tween males and females; however, there are dif- et al. 2012; Gelb and Chung 2014). These genetic ferences by type of CHD with males having a variants disrupt or alter genes that play an im- slightly higher incidence of more severe lesions portant role in normal cardiac development. Al- (Sampayo and Pinto 1994; Moons et al. 2009). though many of the genes and mutations that There are also differences in incidence of specif- increase the risk of developing CHD have been ic lesions based on race and ethnicity. Patent identified, only ∼20%–30% of individuals with ductus arteriosus (PDA) and ventricular septal CHD have an identifiable single genetic factor, defects (VSDs) are more common in Europeans, and this yield varies significantly by cardiac le- whereas atrial septal defects (ASDs) are more sion and whether there are additional medical common in Hispanics (Fixler et al. 1990; Egbe features besides CHD (Grech and Gatt 1999; et al. 2014). The differences observed based on Gelb 2004; Cowan and Ware 2015; Patel et al. gender and race suggest that genetics play an 2016). This work reviews the most common ge- important role in the development of specific netic causes of CHD as well as the known genetic types of CHD, with certain populations having mechanisms. increased genetic susceptibility. The risk of CHD recurrence in the offspring of an affected parent is between 3% and 20% OVERVIEW OF CHD depending on the lesion. Recurrence risk in the CHD is the most common birth defect affecting offspring of women with CHD is about twice as ∼1% of live births, or up to 3% of live births in high as the recurrence in offspring of men with studies that include bicuspid aortic valve (BAV) CHD (Burn et al. 1998). A study from Northern (Hoffman and Kaplan 2002; Calzolari et al. Ireland found that the risk of recurrence of CHD 2003; Tutar et al. 2005; van der Linde et al. for siblings was 3.1%, and siblings had an in- 2011; Egbe et al. 2014). CHD encompasses a creased risk of extracardiac anomalies even in wide spectrum of defects, with varying physio- the absence of CHD (Hanna et al. 1994). Other logic consequences. More severe lesions that re- studies have shown similar risk of recurrence quire multiple surgeries have an incidence of among siblings; more severe types of CHD ∼0.1% of live births (Bernier et al. 2010). Despite have higher recurrence rates (Calcagni et al. significant advances in clinical care, CHD re- 2006; Øyen et al. 2009; Brodwall et al. 2017). mains the leading cause of birth defect–related Lesions with the highest recurrence risk are het- mortality (Boneva et al. 2001; Lee et al. 2001; erotaxy (HTX), right ventricular outflow tract Marelli et al. 2007; Gilboa et al. 2010; Khairy obstruction, and left ventricular outflow tract et al. 2010). Data from the Metropolitan Atlanta obstruction (Loffredo et al. 2004). Approximate- Congenital Heart Defects Program showed a 1- ly one-half of siblings with recurrent CHD have yr survival of 83% for patients with critical CHD a different lesion, supporting the theory that the (Oster et al. 2013). For those patients who sur- etiology of CHD is multifactorial (Oyen et al. vive through infancy, there are still significant 2010). Table 1 describes the estimated recur- lifelong morbidities (Oster et al. 2013; Agarwal rence risk for CHD by lesion and affected family et al. 2014). member. Overall, twins have an increased risk of CHD compared with singleton pregnancies, which is EVIDENCE FOR THE GENETIC BASIS OF CHD thought to be the result of vascular changes re- The etiology of CHD is multifactorial. A genetic lated to a shared placenta (Manning and Archer or environmental cause can be identified in 2006; Herskind et al. 2013; Best and Rankin ∼20%–30% of all cases, and that number is 2015). A population-based Taiwanese study cal- changing as new methods of testing become culated the adjusted risk ratio for CHD with an available (Grech and Gatt 1999; Gelb 2004; affected relative and found that it was 12.03 for a Cowan and Ware 2015; Patel et al. 2016). twin, 4.91 for a first-degree relative, and 1.21 for 284 Cite this article as Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a036749 © 2020 by Cold Spring Harbor Laboratory Press. All rights reserved. This is a free sample of content from Heart Development and Disease. Click here for more information on how to buy the book. Genetic Basis of Human CHD Table 1. Risk of recurrence for common isolated congenital heart disease Lesion Father affected (%) Mother affected (%) One sibling affected (%) Two siblings affected (%) ASD 1.5–3.5 4–6 2.5–38 AVSD 1–4.5 11.5–14 3–410 VSD 2–3.5 6–10 3 10 AS 3–48–18 2 6 PS 2–3.5 4–6.5 2 6 TOF 1.5 2–2.5 2.5–38 CoA 2–34–6.5 2 6 HLHS 21 21 2–96 D-TGA 2 2 1.5 5 Data adapted from Cowan and Ware (2015). See Nora et al. (1988); Nora (1994); Calcagni et al. (2006); Hinton et al. (2007). (AS) Aortic stenosis, (ASD) atrial septal defect, (AVSD) atrioventricular septal defect, (CoA) coarctation of the aorta, (D-TGA) d-loop transposition of the great arteries, (HLHS) hypoplastic left heart syndrome, (PS) pulmonary stenosis, (TOF) tetralogy of Fallot, (VSD) ventricular septal defect. a second-degree relative. They determined that villus sampling (CVS) at 10–11 wk gestation or the phenotypic variance of CHD was 37.3% for amniocentesis after 15–16 wk gestation to ob- familial transmission and 62.8% for non–shared tain placental/fetal DNA. More recently, nonin- environmental factors (Kuo et al. 2018). In a vasive prenatal testing (NIPT) has been used to large Norwegian birth cohort study, the adjusted obtain fetal cell-free DNA from maternal blood relative risk ratio of CHD for siblings of a child to screen for aneuploidies and common dele- with CHD was 14.0 for same-sex twins, 11.9 for tions or duplications, most notably 22q11.2 de- opposite-sex twins, 3.6 for full siblings, and 1.5 letion syndrome (Wapner et al. 2015; Grace et al. for half siblings (Brodwall et al. 2017). These 2016; Dugoff et al. 2017; Gil et al. 2017).
Load more

Recommended publications
  • DE WOLF, of Lyme, Conn
    (tbarles ID'mllolf _ Of Guadaloupe, his Ancestors and Descendants. Being a complete Genealogy of the '' RaoDE lsLAND D'WoLFs," the descendants of SIMON 0& WOLF, with their common descent from BALTHASAR DE WOLF, of Lyme, Conn. (1668) WITH II. BIOGR/1.PHICII.L INTRODUCTION AND APPBICDJCBS ON TH& 1Rova Scotian 4'c -m:rtolf:i • • ~'D OTHER 4JJISD PAXJLID . ' WJTH A PREPACK BY I I BRADFORD COLT DE WOLF BY 11• • REV. CALBRAITH B. PERRY, D. D. • NE\V YORK PRESS OF T. A. WRIGHT 1902 ------- ------- ------- ------- ------- -------- ------- ------- -------- -------- ------- -------- . )\'_ . ' .. ;' , ( ' ' . ,· .' i •. ·.1· .. \ o; ·1: ,> '·: ·,·:.-.1i·.,, .. ,. ' -·-> =-~~-~---·. IIRISTOL, RIIODH ISLANI>. l'Ko,1 A \\' ATRR COLOR BXP.CUTf.11 •·oR TIIIS \'OLV>IB UY llRS. (.OUISA G111soN l'RATT. ------- ------- ------- ------- ------- -------- ------- ------- -------- -------- ------- -------- TO MY PARENTS ]AlllES DE WOLF PERRY WHO WITH SPOTLESS RltPUTATtON MAINTAINBD THE HONOUR OF HIS NAME ; AND JULIA SOPHIA ]ONES PERRY WHO, BY PRECEPT AND JtX.UIPLE. WITH UNTIR.ING APPB.CTION'. TAUGHT HJCJl CHILDREN TO JDfUl.ATB ALL THAT WAS BEST 1:-f -'TJl'atR ANCESTORS, THE POU.OWING PAGAS ARB DBDICATSD WITH GRATEFUL AFFECTION' ------- ------- ------- ------- ------- -------- ------- ------- -------- -------- ------- -------- "'Wle ougbt to keep tbe Beal> before our CJ?es, anl) bonour tbem as tf tbei? were sttu ltvtng" LI Kl OP CONFUCIUS ------- ------- ------- ------- ------- -------- ------- ------- -------- -------- ------- -------- LIST OF ILLUSTRATIONS. View of Bristol, R. I., . • . FronlisjJuee Faclni: PaK• De \Volf Coat.of-Arms, . • . 4 Portrait of Mark Anthony De \Volf, . • 15 Portrait of Abigail Potter De \Volf, . • • 18 Portrait of Hon. James De Wolf, . 23 Portrait of Mrs. Marianne De \Volf Perry, . • 26 View of Parlor at "Silver Creek," . • 31 View of "The Mount" Drawing Room, . 37 Views of "Linden Place," Residence of Col.
    [Show full text]
  • KAT6A Syndrome: Genotype-Phenotype Correlation in 76 Patients with Pathogenic KAT6A Variants
    KAT6A Syndrome: genotype-phenotype correlation in 76 patients with pathogenic KAT6A variants. Item Type Article Authors Kennedy, Joanna;Goudie, David;Blair, Edward;Chandler, Kate;Joss, Shelagh;McKay, Victoria;Green, Andrew;Armstrong, Ruth;Lees, Melissa;Kamien, Benjamin;Hopper, Bruce;Tan, Tiong Yang;Yap, Patrick;Stark, Zornitza;Okamoto, Nobuhiko;Miyake, Noriko;Matsumoto, Naomichi;Macnamara, Ellen;Murphy, Jennifer L;McCormick, Elizabeth;Hakonarson, Hakon;Falk, Marni J;Li, Dong;Blackburn, Patrick;Klee, Eric;Babovic- Vuksanovic, Dusica;Schelley, Susan;Hudgins, Louanne;Kant, Sarina;Isidor, Bertrand;Cogne, Benjamin;Bradbury, Kimberley;Williams, Mark;Patel, Chirag;Heussler, Helen;Duff- Farrier, Celia;Lakeman, Phillis;Scurr, Ingrid;Kini, Usha;Elting, Mariet;Reijnders, Margot;Schuurs-Hoeijmakers, Janneke;Wafik, Mohamed;Blomhoff, Anne;Ruivenkamp, Claudia A L;Nibbeling, Esther;Dingemans, Alexander J M;Douine, Emilie D;Nelson, Stanley F;Arboleda, Valerie A;Newbury-Ecob, Ruth DOI 10.1038/s41436-018-0259-2 Journal Genetics in medicine : official journal of the American College of Medical Genetics Download date 30/09/2021 21:53:13 Link to Item http://hdl.handle.net/10147/627191 Find this and similar works at - http://www.lenus.ie/hse HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Genet Med Manuscript Author . Author manuscript; Manuscript Author available in PMC 2019 October 01. Published in final edited form as: Genet Med. 2019 April ; 21(4): 850–860. doi:10.1038/s41436-018-0259-2. KAT6A Syndrome: Genotype-phenotype correlation in 76 patients with pathogenic KAT6A variants A full list of authors and affiliations appears at the end of the article. Abstract Purpose: Mutations in KAT6A have recently been identified as a cause of syndromic developmental delay.
    [Show full text]
  • Journal of Medical Genetics April 1992 Vol 29 No4 Contents Original Articles
    Journal of Medical Genetics April 1992 Vol 29 No4 Contents Original articles Beckwith-Wiedemann syndrome: a demonstration of the mechanisms responsible for the excess J Med Genet: first published as on 1 April 1992. Downloaded from of transmitting females C Moutou, C Junien, / Henry, C Bonai-Pellig 217 Evidence for paternal imprinting in familial Beckwith-Wiedemann syndrome D Viljoen, R Ramesar 221 Sex reversal in a child with a 46,X,Yp+ karyotype: support for the existence of a gene(s), located in distal Xp, involved in testis formation T Ogata, J R Hawkins, A Taylor, N Matsuo, J-1 Hata, P N Goodfellow 226 Highly polymorphic Xbol RFLPs of the human 21 -hydroxylase genes among Chinese L Chen, X Pan, Y Shen, Z Chen, Y Zhang, R Chen 231 Screening of microdeletions of chromosome 20 in patients with Alagille syndrome C Desmaze, J F Deleuze, A M Dutrillaux, G Thomas, M Hadchouel, A Aurias 233 Confirmation of genetic linkage between atopic IgE responses and chromosome 1 1 ql 3 R P Young, P A Sharp, J R Lynch, J A Faux, G M Lathrop, W 0 C M Cookson, J M Hopkini 236 Age at onset and life table risks in genetic counselling for Huntington's disease P S Harper, R G Newcombe 239 Genetic and clinical studies in autosomal dominant polycystic kidney disease type 1 (ADPKD1) E Coto, S Aguado, J Alvarez, M J Menendez-DIas, C Lopez-Larrea 243 Short communication Evidence for linkage disequilibrium between D16S94 and the adult onset polycystic kidney disease (PKD1) gene S E Pound, A D Carothers, P M Pignatelli, A M Macnicol, M L Watson, A F Wright 247 Technical note A strategy for the rapid isolation of new PCR based DNA polymorphisms P R Hoban, M F Santibanez-Koref, J Heighway 249 http://jmg.bmj.com/ Case reports Campomelic dysplasia associated with a de novo 2q;1 7q reciprocal translocation I D Young, J M Zuccollo, E L Maltby, N J Broderick 251 A complex chromosome rearrangement with 10 breakpoints: tentative assignment of the locus for Williams syndrome to 4q33-q35.1 R Tupler, P Maraschio, A Gerardo, R Mainieri G Lanzi L Tiepolo 253 on September 26, 2021 by guest.
    [Show full text]
  • Advances in Photovoltaics: Part 3 SERIES EDITORS
    VOLUME NINETY SEMICONDUCTORS AND SEMIMETALS Advances in Photovoltaics: Part 3 SERIES EDITORS EICKE R. WEBER Director Fraunhofer-Institut fur€ Solare Energiesysteme ISE Vorsitzender, Fraunhofer-Allianz Energie Heidenhofstr. 2, 79110 Freiburg, Germany CHENNUPATI JAGADISH Australian Laureate Fellow and Distinguished Professor Department of Electronic Materials Engineering Research School of Physics and Engineering Australian National University Canberra, ACT 0200 Australia VOLUME NINETY SEMICONDUCTORS AND SEMIMETALS Advances in Photovoltaics: Part 3 Edited by GERHARD P. WILLEKE Fraunhofer Institute for Solar Energy Systems ISE, Freiburg, Germany EICKE R. WEBER Fraunhofer Institute for Solar Energy Systems ISE, Freiburg, Germany AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 32 Jamestown Road, London NW1 7BY, UK 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA 225 Wyman Street, Waltham, MA 02451, USA The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK First edition 2014 Copyright © 2014 Elsevier Inc. All rights reserved No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions. This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).
    [Show full text]
  • REVIEW ARTICLE Genetic Factors in Congenital Diaphragmatic Hernia
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REVIEW ARTICLE Genetic Factors in Congenital Diaphragmatic Hernia A. M. Holder,* M. Klaassens,* D. Tibboel, A. de Klein, B. Lee, and D. A. Scott Congenital diaphragmatic hernia (CDH) is a relatively common birth defect associated with high mortality and morbidity. Although the exact etiology of most cases of CDH remains unknown, there is a growing body of evidence that genetic factors play an important role in the development of CDH. In this review, we examine key findings that are likely to form the basis for future research in this field. Specific topics include a short overview of normal and abnormal diaphragm development, a discussion of syndromic forms of CDH, a detailed review of chromosomal regions recurrently altered in CDH, a description of the retinoid hypothesis of CDH, and evidence of the roles of specific genes in the development of CDH. Congenital diaphragmatic hernia (CDH [MIM 142340, Overview of Normal and Abnormal Diaphragm 222400, 610187, and 306950]) is defined as a protrusion Development of abdominal viscera into the thorax through an abnormal opening or defect that is present at birth. In some cases, this protrusion is covered by a membranous sac. In con- The development of the human diaphragm occurs be- trast, diaphragmatic eventrations are extreme elevations, tween the 4th and 12th wk of gestation. Traditional views rather than protrusions, of part of the diaphragm that is of diaphragm development suggest that the diaphragm 9 often atrophic and abnormally thin. CDH is a relatively arises from four different structures.
    [Show full text]
  • Further Delineation of the Clinical Spectrum of KAT6B Disorders and Allelic Series of Pathogenic Variants
    ARTICLE © American College of Medical Genetics and Genomics Further delineation of the clinical spectrum of KAT6B disorders and allelic series of pathogenic variants Li Xin Zhang1, Gabrielle Lemire, MD2, Claudia Gonzaga-Jauregui, PhD3, Sirinart Molidperee, Gr. Cert1, Carolina Galaz-Montoya, MD3, David S. Liu, MD3, Alain Verloes, MD PhD4, Amelle G. Shillington, DO5, Kosuke Izumi, MD PhD6, Alyssa L. Ritter, MS LCGC7, Beth Keena, MS LCGC6, Elaine Zackai, MD7,8, Dong Li, PhD9, Elizabeth Bhoj, MD PhD7, Jennifer M. Tarpinian, MS CGC10, Emma Bedoukian, MS LCGC10, Mary K. Kukolich, MD11, A. Micheil Innes, MD12, Grace U. Ediae, BSc13, Sarah L. Sawyer, MD PhD14, Karippoth Mohandas Nair, MD15, Para Chottil Soumya, MD15, Kinattinkara R. Subbaraman, MD15, Frank J. Probst, MD PhD3,16, Jennifer A. Bassetti, MD3,16, Reid V. Sutton, MD3,16, Richard A. Gibbs, PhD3, Chester Brown, MD PhD17, Philip M. Boone, MD PhD18, Ingrid A. Holm, MD MPH18, Marco Tartaglia, PhD19, Giovanni Battista Ferrero, MD PhD20, Marcello Niceta, MD PhD19, Maria Lisa Dentici, MD19, Francesca Clementina Radio, MD PhD19, Boris Keren, MD21, Constance F. Wells, MD22, Christine Coubes, MD22, Annie Laquerrière, MD PhD23, Jacqueline Aziza, MD24, Charlotte Dubucs, MD24, Sheela Nampoothiri, MD25, David Mowat, MD26, Millan S. Patel, MD27, Ana Bracho, MD28, Francisco Cammarata-Scalisi, MD29, Alper Gezdirici, MD30, Alberto Fernandez-Jaen, MD31, Natalie Hauser, MD32, Yuri A. Zarate, MD33, Katherine A. Bosanko, MS CGC33, Klaus Dieterich, MD PhD34, John C. Carey, MD MPH35, Jessica X. Chong, PhD36,37, Deborah A. Nickerson, PhD37,38, Michael J. Bamshad, MD36,37, Brendan H. Lee, MD PhD3, Xiang-Jiao Yang, PhD39, James R.
    [Show full text]
  • Prevalence and Incidence of Rare Diseases: Bibliographic Data
    Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct.
    [Show full text]
  • Orphanet Report Series Rare Diseases Collection
    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic
    [Show full text]
  • Chromosome 20
    Chromosome 20 ©Chromosome Disorder Outreach Inc. (CDO) Technical genetic content provided by Dr. Iosif Lurie, M.D. Ph.D Medical Geneticist and CDO Medical Consultant/Advisor. Ideogram courtesy of the University of Washington Department of Pathology: ©1994 David Adler.hum_20.gif Introduction Chromosome 20 contains about 2% of the whole genetic material. Its genetic length is ~63 Mb. The long arm (~36 Mb) is a little bit larger than the short arm (~27 Mb). Chromosome 20 contains ~700–800 genes. Less than 10% of these genes are known to be related to human diseases. Deletions or duplications of these genes, which may be found in patients with chromosomal abnormalities, cause mostly functional defects, including a delay of psycho–motor development and seizures. Only a few genes may lead (when deleted) to structural defects of the heart, liver, extremities and other organs. Deletions of Chromosome 20 There is a relatively small number of known conditions caused by deletions and duplications of various segments of chromosome 20. Almost all of these deletions and duplications became recognized after usage of molecular cytogenetics. Only a handful of reports on patients with these abnormalities were available only 10 years ago. Because these methods open wide an opportunity to examine abnormalities of this previously not–well studied chromosome, there are no doubts that some new syndromes caused by deletions (or duplications) of chromosome 20 will be delineated in the near future. Currently, the most frequent forms of chromosome 20 deletions are deletions 20p12, involving the JAG1 gene and Alagille syndrome, and deletions 20q13.13q13.2, involving the SALL4 gene.
    [Show full text]
  • 95 Birth Defects Exec Summ
    Executive Summary In 1995, 865 cases of birth defects were detected among live born infants and fetuses of 20 or more weeks gestation delivered to mothers residing in Texas Public Health Regions 6 and 11 (Houston/Galveston region and Lower Rio Grande Valley). In this first full year of the Registry, surveillance was limited to approximately 23 major categories of birth defects, comprising 30 to 40 percent of all known structural malformations. Down syndrome, oral clefts, and spina bifida were the most common birth defects, although some major structural malformations were not yet monitored in 1995. Age Patterns: Both trisomy 21 (Down syndrome) and trisomy 18 (Edwards syndrome) demonstrated an age-specific rate pattern that was J-shaped, with the highest birth prevalence (“rates”) observed among mothers 35 years of age and older. Gastroschisis, a malformation of the abdominal wall, exhibited highest rates among the youngest mothers and decreased with each older age group. Racial/Ethnic Patterns: Anencephaly and spina bifida were lowest among African Americans; however, rates were similar in whites and Hispanics. Among the heart defects, relatively high rates of tetralogy of Fallot were observed among African Americans, although they exhibited relatively low rates of hypoplastic left heart. Cleft palate alone was more likely to occur among whites and Hispanics. Rates of trisomy 18 (Edwards syndrome) were highest among African Americans and whites. Gender Patterns: With regard to sex, higher rates were documented among females for anencephaly, and to a lesser extent, spina bifida. Females experienced two-fold higher rates of trisomy 18 (Edwards syndrome). Males had higher rates of cleft lip with or without cleft palate.
    [Show full text]
  • Genetic Testing Options
    GENETIC TESTING OPTIONS Most babies are born free of birth defects. Of those who are affected, the more common types are Trisomy defects, such as Down syndrome, and Open Neural Tube defects such as Spina Bifida. Testing is optional. Some people want genetic testing done as early as possible, to reassure them that their baby is normal, or to provide a diagnosis early enough in the pregnancy so that all options remain open. Others, who would not change their pregnancy plans in the event of a birth defect, seek to know whether the baby is normal or affected, and if there is a birth defect, to use the remainder of the pregnancy to educate themselves and prepare for a family member with special needs. It is also helpful for your doctor to be prepared for all eventualities. Still others prefer not to undergo any genetic testing. Our goal is to educate you about the options so that you can make a fully informed decision, as well as to support your decision. SCREENING TESTS A screening test is NOT the same as a diagnostic test. The screening process is basically a customized statistical risk assessment, to determine your personal risk. A positive screening test is NOT a diagnosis of a birth defect. It provides information that guides decisions about diagnostic testing. First Look Test (typically scheduled between 12wks-13wks 3days) The First Look Test is offered at Emerson Hospital MFM by Brigham & Women’s perinatologists and at Brigham & Women’s Hospital. It is a non-invasive test that assesses whether you are at increased risk of having a baby with Down syndrome or Trisomy 18.
    [Show full text]
  • Its Place Among Other Genetic Causes of Renal Disease
    J Am Soc Nephrol 13: S126–S129, 2002 Anderson-Fabry Disease: Its Place among Other Genetic Causes of Renal Disease JEAN-PIERRE GRU¨ NFELD,* DOMINIQUE CHAUVEAU,* and MICHELINE LE´ VY† *Service of Nephrology, Hoˆpital Necker, Paris, France; †INSERM U 535, Baˆtiment Gregory Pincus, Kremlin- Biceˆtre, France. In the last two decades, decisive advances have been made in Nephropathic cystinosis, first described in 1903, is an auto- the field of human genetics, including renal genetics. The somal recessive disorder characterized by the intra-lysosomal responsible genes have been mapped and then identified in accumulation of cystine. It is caused by a defect in the transport most monogenic renal disorders by using positional cloning of cystine out of the lysosome, a process mediated by a carrier and/or candidate gene approaches. These approaches have that remained unidentified for several decades. However, an been extremely efficient since the number of identified genetic important management step was devised in 1976, before the diseases has increased exponentially over the last 5 years. The biochemical defect was characterized in 1982. Indeed cysteam- data derived from the Human Genome Project will enable a ine, an aminothiol, reacts with cystine to form cysteine-cys- more rapid identification of the genes involved in the remain- teamine mixed disulfide that can readily exit the cystinotic ing “orphan” inherited renal diseases, provided their pheno- lysosome. This drug, if used early and in high doses, retards the types are well characterized. We have entered the post-gene progression of cystinosis in affected subjects by reducing intra- era. What is/are the function(s) of these genes? What are the lysosomal cystine concentrations.
    [Show full text]